BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) has hailed the positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus (COVID-19) reduces the need for intensive care.
Data from the Synairgen PLC (LON:SNG) trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given the placebo.
READ: Synairgen rockets as trial results could signal "major breakthrough" in treatment of severely ill COVID-19 patients
They were also more than twice as likely to recover from the illness than those receiving the substance with no therapeutic value.
The treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus, noted BetterLife in a statement on Tuesday.
BetterLife is an advocate of using interferons to treat coronavirus, particularly delivered by an inhalation device.
It is aiming to carry out a clinical trial this summer to test to treat patients afflicted with the virus and hopes the nebulizer, along with its patent-pending interferon alpha2b drug, called AP-003, will help patients.
The treatment in the Synairgen study used interferon beta, as opposed to the alpha 2b (IFN-a2b) treatment developed by the company.
"We are encouraged by the positive results from this trial as it further confirms the proof of concept of anti-COVID treatment via IFN inhalation," Ahmad Doroudian, the chief executive officer of BetterLife said in the statement. "We look forward to our proposed 150 patient clinical trials using AP-003 (inhaled IFN alpha 2b) in COVID-19 patients."
He added: "BetterLife’s team believes that the isoform-free IFN alpha2b will provide a potentially superior treatment regimen for Covid-19 patients, as IFN-a2b has already been used to successfully treat other viral infections such as HCV and HBV."
Shares in Toronto gained over 4.6% to C$2.46.
---Updates for share price---
Contact the author at firstname.lastname@example.org